Search research articles
Contact Us
Filters
Showing results (21-30 of 32) with videos related to
Page
of 4
Sort By:
Medrxiv : the Preprint Server for Health Sciences
|
February 12, 2026
Personalized Circulating Tumor DNA (ctDNA) Profiling Enables Superior and Universal Measurable Residual Disease (MRD) Detection in Acute Myeloid Leukemia (AML)
Ruwan Gunaratne, Crystal Zhou, Sanjeeth Rajaram, et al.
Ejhaem
|
May 14, 2025
Phase 2 Multi-Arm Study of Magrolimab Combinations in Patients With Acute Myeloid Leukaemia
Gabriel N Mannis, Camille N Abboud, Naval G Daver, et al.
Blood Neoplasia
|
September 8, 2025
A phase 1 study of IO-202, an anti-LILRB4 antibody, in chronic myelomonocytic leukemia and acute myeloid leukemia
Ahmed Aribi, Gabriel N Mannis, Yazan F Madanat, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
March 18, 2015
A phase I study of targeted, dose-escalated intravenous busulfan in combination with etoposide as myeloablative therapy for autologous stem cell transplantation in acute myeloid leukemia
Gabriel N Mannis, Charalambos Andreadis, Aaron C Logan, et al.
The New England Journal of Medicine
|
June 3, 2026
All-Oral Treatment of Newly Diagnosed Acute Myeloid Leukemia
Gail J Roboz, Amer M Zeidan, Gabriel N Mannis, et al.
Blood Cancer Discovery
|
September 13, 2021
Inhibition of MET Signaling with Ficlatuzumab in Combination with Chemotherapy in Refractory AML: Clinical Outcomes and High-Dimensional Analysis
Victoria E Wang, Bradley W Blaser, Ravi K Patel, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 9, 2024
Menin Inhibition With Revumenib for <i>KMT2A</i>-Rearranged Relapsed or Refractory Acute Leukemia (AUGMENT-101)
Ghayas C Issa, Ibrahim Aldoss, Michael J Thirman, et al.
Blood
|
December 17, 2019
Ivosidenib induces deep durable remissions in patients with newly diagnosed IDH1-mutant acute myeloid leukemia
Gail J Roboz, Courtney D DiNardo, Eytan M Stein, et al.
Blood
|
May 7, 2025
Menin inhibition with revumenib for NPM1-mutated relapsed or refractory acute myeloid leukemia: the AUGMENT-101 study
Martha L Arellano, Michael J Thirman, John F DiPersio, et al.
Blood
|
January 26, 2026
Oncogenic SF3B1 mutations alter the splicing of mRNA noncoding regions to induce a novel therapeutic vulnerability
Michal Sekrecki, Agata Sekrecka, Rohan R Lattupally, et al.
Page
of 4
Search research articles
Search
Showing results (21-30 of 32) with videos related to
Sort By:
Page
of 4
Medrxiv : the Preprint Server for Health Sciences
|
February 12, 2026
Personalized Circulating Tumor DNA (ctDNA) Profiling Enables Superior and Universal Measurable Residual Disease (MRD) Detection in Acute Myeloid Leukemia (AML)
Ruwan Gunaratne, Crystal Zhou, Sanjeeth Rajaram, et al.
Ejhaem
|
May 14, 2025
Phase 2 Multi-Arm Study of Magrolimab Combinations in Patients With Acute Myeloid Leukaemia
Gabriel N Mannis, Camille N Abboud, Naval G Daver, et al.
Blood Neoplasia
|
September 8, 2025
A phase 1 study of IO-202, an anti-LILRB4 antibody, in chronic myelomonocytic leukemia and acute myeloid leukemia
Ahmed Aribi, Gabriel N Mannis, Yazan F Madanat, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
March 18, 2015
A phase I study of targeted, dose-escalated intravenous busulfan in combination with etoposide as myeloablative therapy for autologous stem cell transplantation in acute myeloid leukemia
Gabriel N Mannis, Charalambos Andreadis, Aaron C Logan, et al.
The New England Journal of Medicine
|
June 3, 2026
All-Oral Treatment of Newly Diagnosed Acute Myeloid Leukemia
Gail J Roboz, Amer M Zeidan, Gabriel N Mannis, et al.
Blood Cancer Discovery
|
September 13, 2021
Inhibition of MET Signaling with Ficlatuzumab in Combination with Chemotherapy in Refractory AML: Clinical Outcomes and High-Dimensional Analysis
Victoria E Wang, Bradley W Blaser, Ravi K Patel, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 9, 2024
Menin Inhibition With Revumenib for <i>KMT2A</i>-Rearranged Relapsed or Refractory Acute Leukemia (AUGMENT-101)
Ghayas C Issa, Ibrahim Aldoss, Michael J Thirman, et al.
Blood
|
December 17, 2019
Ivosidenib induces deep durable remissions in patients with newly diagnosed IDH1-mutant acute myeloid leukemia
Gail J Roboz, Courtney D DiNardo, Eytan M Stein, et al.
Blood
|
May 7, 2025
Menin inhibition with revumenib for NPM1-mutated relapsed or refractory acute myeloid leukemia: the AUGMENT-101 study
Martha L Arellano, Michael J Thirman, John F DiPersio, et al.
Blood
|
January 26, 2026
Oncogenic SF3B1 mutations alter the splicing of mRNA noncoding regions to induce a novel therapeutic vulnerability
Michal Sekrecki, Agata Sekrecka, Rohan R Lattupally, et al.
Page
of 4